Sygnature Discovery, a U.K.-based preclinical contractor, is pumping 3.75 million pounds sterling ($4.6 million) into Azenta Life Sciences’ compound management storage system that will allow it to store customer libraries.

总部位于英国的临床前承包商Sygnature Discovery正在向Azenta Life Sciences的复合管理存储系统中注入375万英镑（460万美元），该系统将允许它存储客户库。

Azenta’s service, along with high-throughput screening (HTS) capacity, will allow automated management and screening of compounds from various sources at one location, according to a Nov. 2 press release. With it, Sygnature will be able to store more than 2 million compounds under optimal conditions for stability, and compound samples will be tracked automatically from the storage well to the final HTS assay data point..

根据11月2日的新闻稿，Azenta的服务以及高通量筛选（HTS）能力将允许在一个位置对来自不同来源的化合物进行自动化管理和筛选。有了它，Sygnature将能够在最佳稳定性条件下储存200多万种化合物，化合物样品将从储存井自动跟踪到最终的HTS测定数据点。。

The investment is part of Sygnature’s goal to become a market leader in the drug discovery market for hit-finding capabilities.

这项投资是Sygnature目标的一部分，该目标是成为药物发现市场中具有命中发现能力的市场领导者。

In August, Sygnature bought Canadian CRO NuChem Sciences for an undisclosed price, giving the company integrated and standalone discovery services that span medicinal, synthetic, scale-up, process and computational chemistry as well as drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology..

8月，Sygnature以未公开的价格收购了加拿大CRO NuChem Sciences，为该公司提供了集成和独立的发现服务，涵盖药物，合成，放大，过程和计算化学以及药物代谢和药代动力学，体外生物学和体内药理学。。